AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 JAN 1 - (NewsRx.com & NewsRx.net) -- "The development of immunotherapy for cancer, such as synthetic peptide-based vaccines, relies heavily on the identification of appropriate epitopes capable of eliciting antitumor T-cell responses," note Mayo Clinic immunologists.
"We have used a combination of computer-based algorithms to predict peptide sequences from prostate-specific membrane antigen (PSMA) capable of stimulating in vitro CTLs [cytotoxic T lymphocytes] restricted by the HLA-A2 MHC [major histocompatibility complex] molecule," wrote J. Lu and colleagues, Mayo Clinic & Mayo Foundation, Department of Immunology.
"Four of the five peptides that were predicted by these algorithms were capable of inducing antigen-specific CTLs that killed target cells that were pulsed exogenously with the corresponding peptides," the researchers said. "However, only one of the four peptides, PSMA(27), induced CTLs that were effective at recognizing prostate tumor cells expressing the HLA-A2 and PSMA ...